Healthcare Analysts discuss novel treatments for ulcerative colitis and provide a preview for upcoming Phase 3 results for Abivax’s (ABVX) Obefazimod (ABVX PTGX) on an Analyst/Industry conference call to be held on July 16.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABVX:
- Abivax’s Obefazimod: A Promising Contender in Ulcerative Colitis Treatment with Potential Market Impact
- Positive Outlook for Abivax SA: Anticipated Success of Obefazimod in Ulcerative Colitis Treatment
- Buy Rating Justified for Abivax SA: Promising Efficacy of Obefazimod in Ulcerative Colitis and Crohn’s Disease
- Abivax’s Potential in IBD Market: Buy Rating Backed by Phase 3 Trials and Industry Trends
- Abivax SA Shareholders Approve 2024 Financials and Board Appointments